8-K: Cocrystal Pharma Appoints New CEO, Adjusts Leadership

Cocrystal Pharma, Inc. announced the immediate appointment of James Sapirstein as Chief Executive Officer, effective June 3, 2026, alongside a new stock option grant.

Summary

• Cocrystal Pharma, Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective June 3, 2026.
• Mr. Sapirstein will receive an initial annual base salary of $265,000 and a potential annual performance bonus of 50% of his base salary.
• He has been granted 10-year stock options to purchase 235,000 shares at an exercise price of $1.05, vesting over four years.
• Additional stock options for another 235,000 shares may be granted after six months, subject to performance and continued employment.
• James Martin and Sam Lee, the former Co-CEOs, will continue in their roles as Chief Financial Officer and President/Chief Scientific Officer, respectively.
• There are no disclosed arrangements, understandings, family relationships, or related party transactions concerning Mr. Sapirstein's appointment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it brings in new leadership with relevant experience and provides incentives, but the actual impact depends on future performance and strategic execution.

Positives

• Appointment of a new CEO with prior experience as CEO of a biopharmaceutical company.
• Stock option grants to incentivize the new CEO and align interests with shareholders.
• Clear vesting schedule and provisions for acceleration upon Change in Control or termination without Cause.
• Existing Co-CEOs remain in their critical roles, ensuring continuity in finance and scientific leadership.

Negatives

• The filing does not provide specific performance targets for the bonus or the second stock option grant.
• The stock option exercise price of $1.05 is based on the closing price on the grant date, which could be subject to market fluctuations.

Risks

• The success of the company may depend on the new CEO's ability to achieve performance targets and drive strategic initiatives.
• Vesting of stock options is subject to continued employment, creating a retention risk if the CEO departs before vesting is complete.
• Potential for future dilution if a significant number of stock options are exercised.

Future Outlook

The company's future outlook will be influenced by the new CEO's leadership, the achievement of performance targets for bonuses and future stock options, and the successful development of its therapeutic pipeline.

Management Comments

• James Sapirstein is entitled to an initial annual base salary of $265,000.
• Mr. Sapirstein is eligible for an annual performance bonus equal to 50% of his base salary, based on performance targets.
• The initial stock option grant is exercisable at $1.05 and vests over four years, with provisions for acceleration.
• A subsequent grant of options for an additional 235,000 shares is possible on the six-month anniversary, subject to conditions.

Industry Context

StockSavvy.ai notes that executive leadership changes are common in the biopharmaceutical sector, often signaling a strategic shift or a renewed focus on growth and development. The appointment of a CEO with prior experience in the industry, coupled with equity incentives, is a standard practice to align leadership with shareholder value.

Comparison to Industry Standards

• The base salary of $265,000 for a new CEO in a biopharmaceutical company is within the typical range, especially for companies of Cocrystal Pharma's size and stage.
• The potential for a 50% performance bonus is a standard incentive structure, contingent on achieving predefined targets.
• The stock option grant of 235,000 shares, with an exercise price at or near the market price, is a common method to motivate executives and retain talent in the biotech industry, similar to practices seen at companies like Moderna or BioNTech during their growth phases.

Management Changes

Stakeholder Impact

• Shareholders: Potential for improved strategic direction and performance under new leadership, with incentives tied to stock performance.
• Employees: May experience shifts in company culture and strategic priorities under the new CEO.
• Management: Continuity for Sam Lee (President/CSO) and James Martin (CFO) in their existing roles.

Next Steps

• Monitor the performance of James Sapirstein as CEO.
• Observe the achievement of performance targets for bonus and future stock option grants.
• Track the vesting of stock options for Mr. Sapirstein.
• Evaluate the company's strategic direction under new leadership.

Key Dates

Recommendation

The appointment of a new CEO is a significant event that could impact future performance. However, without further information on the company's strategic plans under this new leadership or recent financial performance, a 'hold' recommendation is prudent. Investors should await further developments and strategic updates before considering a change in position.

Keywords

CEO Appointment, Cocrystal Pharma, James Sapirstein, Stock Options, Executive Leadership, Biopharmaceutical, Form 8-K, Corporate Governance